regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Company profile
Ticker
RGNX
Exchange
Website
CEO
Kenneth Mills
Employees
Location
Fiscal year end
Industry (SIC)
Former names
ReGenX Biosciences, LLC
SEC CIK
Corporate docs
Subsidiaries
REGENXBIO EU Limited ...
RGNX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
8-K
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
11 Mar 24
424B5
Prospectus supplement for primary offering
8 Mar 24
FWP
Free writing prospectus
7 Mar 24
424B5
Prospectus supplement for primary offering
6 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
27 Feb 24
Transcripts
RGNX
Earnings call transcript
2023 Q4
27 Feb 24
RGNX
Earnings call transcript
2023 Q3
8 Nov 23
RGNX
Earnings call transcript
2023 Q2
2 Aug 23
RGNX
Earnings call transcript
2023 Q1
3 May 23
RGNX
Earnings call transcript
2022 Q4
28 Feb 23
RGNX
Earnings call transcript
2022 Q3
3 Nov 22
RGNX
Earnings call transcript
2022 Q2
5 Aug 22
RGNX
Earnings call transcript
2022 Q1
5 May 22
RGNX
Earnings call transcript
2021 Q4
2 Mar 22
RGNX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Kenneth T. Mills
17 Apr 24
4
Vittal Vasista
21 Mar 24
4
Kenneth T. Mills
18 Mar 24
4
STEVE PAKOLA
7 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Kenneth T. Mills
16 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
GIC Private Ltd
5 Feb 24
SC 13G/A
JPMORGAN CHASE & CO
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 55.30 mm | 55.30 mm | 55.30 mm | 55.30 mm | 55.30 mm | 55.30 mm |
Cash burn (monthly) | 5.19 mm | 5.44 mm | 21.65 mm | 22.06 mm | 16.47 mm | 18.08 mm |
Cash used (since last report) | 35.32 mm | 37.06 mm | 147.51 mm | 150.28 mm | 112.19 mm | 123.20 mm |
Cash remaining | 19.98 mm | 18.24 mm | -92.21 mm | -94.98 mm | -56.89 mm | -67.90 mm |
Runway (months of cash) | 3.9 | 3.4 | -4.3 | -4.3 | -3.5 | -3.8 |
Institutional ownership, Q3 2023
78.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 154 |
Opened positions | 16 |
Closed positions | 25 |
Increased positions | 61 |
Reduced positions | 50 |
13F shares | Current |
---|---|
Total value | 601.16 bn |
Total shares | 38.66 mm |
Total puts | 122.70 k |
Total calls | 263.00 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.03 mm | $132.12 bn |
Vanguard | 4.38 mm | $72.04 bn |
JPM JPMorgan Chase & Co. | 3.67 mm | $60.33 bn |
Redmile | 2.57 mm | $42.37 bn |
STT State Street | 2.50 mm | $41.21 bn |
Kiser 2012 Gift Trust | 1.91 mm | $86.72 mm |
Dimensional Fund Advisors | 1.19 mm | $19.63 bn |
Geode Capital Management | 883.15 k | $14.54 bn |
Aquilo Capital Management | 847.42 k | $13.95 bn |
Balyasny Asset Management | 787.62 k | $12.96 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Kenneth T. Mills | Common Stock | Sell | Dispose S | No | Yes | 18.1914 | 15,000 | 272.87 k | 408,035 |
15 Apr 24 | Kenneth T. Mills | Common Stock | Option exercise | Acquire M | No | Yes | 3.76 | 15,000 | 56.40 k | 423,035 |
15 Apr 24 | Kenneth T. Mills | Stock Options Common Stock | Option exercise | Dispose M | No | Yes | 3.76 | 15,000 | 56.40 k | 96,354 |
19 Mar 24 | Vasista Vittal | Common Stock | Option exercise | Acquire M | No | No | 3.76 | 20,041 | 75.35 k | 246,534 |
19 Mar 24 | Vasista Vittal | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.76 | 20,041 | 75.35 k | 0 |
14 Mar 24 | Kenneth T. Mills | Common Stock | Sell | Dispose S | No | Yes | 21.8628 | 15,000 | 327.94 k | 408,035 |
14 Mar 24 | Kenneth T. Mills | Common Stock | Option exercise | Acquire M | No | Yes | 3.76 | 15,000 | 56.40 k | 423,035 |
14 Mar 24 | Kenneth T. Mills | Stock Options Common Stock | Option exercise | Dispose M | No | Yes | 3.76 | 15,000 | 56.40 k | 111,354 |
5 Mar 24 | Steve Pakola | Common Stock | Sell | Dispose S | No | Yes | 28.36 | 12,878 | 365.22 k | 107,192 |
5 Mar 24 | Steve Pakola | Common Stock | Option exercise | Acquire M | No | Yes | 22.25 | 12,878 | 286.54 k | 120,070 |
News
Where Regenxbio Stands With Analysts
12 Apr 24
Stifel Maintains Buy on Regenxbio, Maintains $40 Price Target
12 Apr 24
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
28 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
25 Mar 24
HC Wainwright & Co. Initiates Coverage On Regenxbio with Buy Rating, Announces Price Target of $36
11 Mar 24
Press releases
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
28 Mar 24
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
27 Mar 24
REGENXBIO to Participate in Upcoming Investor Conferences
11 Mar 24
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
6 Mar 24
REGENXBIO Announces Proposed Public Offering of Common Stock
6 Mar 24